
Immatics Biotechnologies and The University of Texas MD Anderson Cancer Center (MDACC) have together launched a new company focusing on …
A new MicroRNA treatment for prostate cancer has been highly effective against the disease in pre-clinical studies. MicroRNAs, or miRNAs, …

